4.5 Article

Epigenetic silencing of DSC3 is a common event in human breast cancer

Journal

BREAST CANCER RESEARCH
Volume 7, Issue 5, Pages R669-R680

Publisher

BMC
DOI: 10.1186/bcr1273

Keywords

-

Categories

Funding

  1. NATIONAL CANCER INSTITUTE [R01CA075152, P01CA056666, R56CA073612, R29CA073612, R01CA073612, T32CA009213, R29CA065662, R01CA065662, P30CA023074] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007091] Funding Source: NIH RePORTER
  3. NCI NIH HHS [P01 CA056666, T32 CA09213, CA75152, R01 CA073612, R56 CA073612, CA56666, P01 CA056666-090002, R29 CA073612, R01 CA075152-06, T32 CA009213, R01 CA075152, R01 CA065662, CA65662, R29 CA065662, CA73612, P30 CA023074, P30 CA23074] Funding Source: Medline
  4. NIEHS NIH HHS [ES07091, T32 ES007091] Funding Source: Medline

Ask authors/readers for more resources

Introduction Desmocollin 3 (DSC3) is a member of the cadherin superfamily of calcium-dependent cell adhesion molecules and a principle component of desmosomes. Desmosomal proteins such as DSC3 are integral to the maintenance of tissue architecture and the loss of these components leads to a lack of adhesion and a gain of cellular mobility. DSC3 expression is down-regulated in breast cancer cell lines and primary breast tumors; however, the loss of DSC3 is not due to gene deletion or gross rearrangement of the gene. In this study, we examined the prevalence of epigenetic silencing of DSC3 gene expression in primary breast tumor specimens. Methods We used bisulfite genomic sequencing to analyze the methylation state of the DSC3 promoter region from 32 primary breast tumor specimens. We also used a quantitative real-time RT-PCR approach, and analyzed all breast tumor specimens for DSC3 expression. Finally, in addition to bisulfite sequencing and RT-PCR, we used an in vivo nuclease accessibility assay to determine the chromatin architecture of the CpG island region from DSC3-negative breast cancer cells lines. Results DSC3 expression was downregulated in 23 of 32 (72%) breast cancer specimens comprising: 22 invasive ductal carcinomas, 7 invasive lobular breast carcinomas, 2 invasive ductal carcinomas that metastasized to the lymph node, and a mucoid ductal carcinoma. Of the 23 specimens showing a loss of DSC3 expression, 13 (56%) were associated with cytosine hypermethylation of the promoter region. Furthermore, DSC3 expression is limited to cells of epithelial origin and its expression of mRNA and protein is lost in a high proportion of breast tumor cell lines (79%). Lastly, DNA hypermethylation of the DSC3 promoter is highly correlated with a closed chromatin structure. Conclusion These results indicate that the loss of DSC3 expression is a common event in primary breast tumor specimens, and that DSC3 gene silencing in breast tumors is frequently linked to aberrant cytosine methylation and concomitant changes in chromatin structure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available